Interferon Lambda: The Unsung Hero in the Fight Against Cancer?
"Discover how this unique type III interferon could revolutionize cancer treatment by offering a dual role: suppressing tumors and modulating the immune response."
In the ever-evolving landscape of cancer research, a new player has emerged, capturing the attention of scientists and clinicians alike: Interferon Lambda (IFN-λ). As a member of the type III interferon family, IFN-λ shares structural similarities with its better-known counterparts, the type I interferons (IFN-α/β). However, IFN-λ boasts unique biological functions that set it apart, most notably in the realm of tumor suppression. It acts as an antiviral agent, but it's its potential in cancer therapy that's generating excitement.
While IFN-λ activates the same Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways as IFN-α/β, it exhibits a distinctive ability to selectively induce the expression of interferon-stimulated genes (ISGs). This nuanced approach allows IFN-λ to act differently under various physiological and pathological conditions. Specifically, unlike IFN-α/β, IFN-λ doesn't contribute to overstimulation of the immune response or the exacerbation of inflammation.
Yet, as research deepens, unexpected characteristics of IFN-λ are coming to light. It appears that IFN-λ plays a role not only in controlling inflammation but also in promoting immune suppression and, paradoxically, cancer progression under certain conditions. This revelation presents both challenges and opportunities. Understanding these complexities could pave the way for more strategic and effective cancer therapies, moving beyond traditional approaches.
A Cytokine That Punches Above Its Weight
Interferon lambda is a type III interferon cytokine whose antiviral activity is mediated through the IFNLR1/IL10RB receptor dimer, which binds the ligands IFNL2 and IFNL3. Its clinical footprint has grown markedly in recent years, exemplified by an NEJM-reported trial of pegylated interferon lambda as a conveniently administered antiviral therapy for outpatients with Covid-19. The picture is not uniformly positive, however: PNAS research found that interferon lambda promotes systemic immune dysregulation through localized effects in the skin and kidneys, implicating the cytokine in lupus immunobiology and tissue-specific pathology.
From Antiviral Therapy to Nasal Spray Delivery
The accepted approach positions interferon lambda as an antiviral therapy, and a published review examines what is known about its role in treating Covid-19, including potential limitations and how the approach might be used in the future (ClinicalTrials.gov NCT04331899). To overcome the traditional limitations of interferon-lambda therapeutics, KAIST researchers report an AI-engineered variant delivered via nasal spray, using structural modifications and an advanced delivery system built on nanoliposomes and a chitosan coating. In herpes stromal keratitis, interferon lambda (IL-28A) begun before or early during infection proved a potent inhibitor of lesion development, acting not only by suppressing viral replication but also by reducing the cellular and cytokine mediators of the disease. As the Altmeyers encyclopedia notes, interferons are signaling proteins that are part of the immune response to viral infections and to some other conditions, including certain cancers and autoimmune diseases.
From Discovery Milestones to Hepatitis Trials
A comprehensive review traces the historical milestones of interferon research and charts the clinical trials of pegylated-interferon lambda in patients infected with hepatitis B, C, and D virus. Building on that history, foundational work established that lambda interferon is a type III interferon induced by viruses and by interferons themselves, displaying potent antiviral activity against select virus infections in vivo. Notably, interferon-lambda-treated dendritic cells were found to specifically induce the proliferation of FOXP3-expressing suppressor T cells, hinting that its influence extends to immune regulation rather than purely direct antiviral effects.
The Dual Role of IFN-λ in Cancer: A Closer Look
The epithelium, a tightly packed layer of cells that forms the body's first line of defense against external threats, is particularly susceptible to infections, inflammation, and cancer. Interestingly, IFN-λ exhibits a preferential expression in epithelial cells, sparking significant interest in its role in viral infections and cancers affecting these tissues. While our knowledge of the IFN-λ system is largely derived from studies on mice and human cell lines, insights are rapidly expanding. Unlike mouse hepatocytes, human hepatocytes are highly sensitive to IFN-λ, hinting at species-specific nuances that require further investigation.
- Direct Antitumor Effects: IFN-λ can directly inhibit cell proliferation and induce apoptosis in tumor cells.
- Indirect Antitumor Effects: IFN-λ activates immune cells and inhibits angiogenesis, cutting off the blood supply to tumors.
- Immune Cell Activation: IFN-λ can stimulate T cell responses in various cancers, enhancing the body's natural ability to fight tumors.
- Angiogenesis Inhibition: IFN-λ has been shown to suppress tumor angiogenesis, further limiting tumor growth and spread.
Four Isoforms, One Expanding Portfolio
The type III interferon family, known as interferon lambda, consists of four isoforms (IFN-λ1, IFN-λ2, IFN-λ3, and IFN-λ4) that play essential roles in immune responses. Reviews now frame IFN-λ as having dual roles in both anti-viral defense and cancer, examining its mechanisms and therapeutic potential. Its relevance to respiratory viral infections is a major focus, with influenza cited as a prime example and a major public health problem responsible for up to half a million lethal infections annually. A separate update likewise evaluates the potential role of interferon-lambda in the treatment of inflammation and cancer.
When the Same Cytokine Backfires
Counterarguments come from the autoimmune side of the ledger, where a Nature Reviews Rheumatology discussion reports that interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. The same source also points to a mechanistic wrinkle: differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. These findings, as reported by that review, suggest that the very signaling that makes IFN-λ a useful antiviral can fuel disease when dysregulated.
A Gentler Cousin of Type I Interferons
Interferon lambda is a type III interferon that activates the same antiviral mechanisms as type I interferons, but it acts primarily on epithelial cells. Because its receptors are less widely expressed, IFN-λ causes fewer systemic side effects. In hepatitis C, genome-wide association studies point to IFN-λ as a key cytokine in the control of HCV infection, cementing its standing among the interferons. Its signaling pathway is frequently compared side by side with that of type I and type II interferons to explain these differences in tissue activity and tolerability.
The Future of IFN-λ in Cancer Therapy
Since its initial recognition as a potent antitumor agent with limited side effects compared to IFN-α, IFN-λ has emerged as a promising candidate in immuno-oncology. However, the evolving understanding of its dual role in cancer underscores the need for careful consideration and strategic application. By dissecting the mechanisms through which IFN-λ both suppresses and promotes cancer, researchers aim to identify novel molecular and immunological targets that will pave the way for more effective and personalized cancer therapies. This nuanced approach promises to unlock the full potential of IFN-λ, transforming it from a promising agent into a cornerstone of cancer treatment.
Genetic Fingerprints of Response
Expert synthesis highlights genetics as the strongest link between IFN-λ and clinical outcomes: interferon lambda 3 (IFN-λ3) polymorphisms are the strongest genetic predictor of hepatitis C virus outcome and of response to pegylated interferon (PegIFN)-based therapy. Whether this holds true for hepatitis B virus infection, however, is reported to be a matter of controversy. Commentary also situates the cytokine in the broader landscape of inflammation and autoimmune rheumatic diseases, where the same signaling pathways that fight infection can contribute to pathology.
Lowering Viral Loads and Calming the Fire
The development pipeline has long included pegylated versions of the cytokine: ZymoGenetics and Bristol-Myers Squibb presented phase 2a interim data on PEG-interferon lambda, including clinical, pharmacokinetic, and viral kinetic data, along with in vitro data combining it with direct-acting antiviral agents. Looking ahead, commentary accompanying the NEJM Covid-19 trial argues that treatment with interferon lambda appears attractive not just for reducing viral load but also for reducing hyperinflammation, an important aspect that was not addressed in the trial but certainly deserves evaluation in future studies.
More Than an Infection Alarm
A recent review positions interferon-lambdas (IFN-λs) as critical mediators of antiviral defense at mucosal surfaces. The same review notes that beyond their established role in regulating innate immune responses during infection, recent evidence shows IFN-λs are constitutively expressed even in pathogen-free environments. This suggests the cytokine's functions extend well beyond acute infection control into baseline physiology, which the review frames as an important area for continued investigation.
From Clinic to Community
At Stanford Medicine, the Lambda Study ran a clinical trial of "Lambda Interferón" for the treatment of Covid-19, with outreach materials offered in both English and Spanish to reach the affected community. Researchers including Ludmila Prokunina-Olsson and Noémie Alphonse made the case for interferon lambda as a therapy for Covid-19 and other emerging viral infections. A Toronto study found that interferon sped Covid-19 recovery, and, unlike antibodies, interferon lambda has the advantage that its effectiveness does not depend on interacting directly with the coronavirus, so its power remains undiminished even when infection is caused by a new variant.